IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors. The safety and tolerability of the study drug(s) will also be studied.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat w momencie włączenia do badania
- •Potwierdzony zaawansowany nowotwór litego przy badaniu histologicznym lub cytologicznym
- •Podpisana świadoma zgoda na udział w badaniu
- •Nowotwór z określonymi mutacjami genetycznymi (KEAP1, NFE2L2, STK11, NF1, PIK3CA, AKT, PTEN) lub niskim poziomem ekspresji białka ASNS
- •Dla raka jajnika: nawrót raka o wysokim złośliwości, oporny na chemioterapię platynową (nawrót w ciągu 6 miesięcy), otrzymanie mniej niż 5 wcześniejszych schematów leczenia
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- October 6, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (1)
M D Anderson Cancer Center
Houston, United States
Trial contact
Timothy A Yap, MD
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 10/7/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.